---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-098229"
form_type: "8-K"
ticker: "TRVI"
cik: "0001563880"
company_name: "Trevi Therapeutics, Inc."
filed_at: "2022-04-07T23:59:59+00:00"
generated_at: "2026-06-26T08:47:39.804636+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Trevi Therapeutics raises ~$55M in private placement; amends SVB loan facility

## Summary
- Gross proceeds ~$55M from sale of 4.58M shares at $1.90/share and pre-funded warrants for 24.38M shares at $1.899.
- Co-lead investors: Frazier Life Sciences and Venrock; also Fairmount and New Enterprise Associates participating.
- Proceeds to fund clinical development of Haduvio for chronic cough in IPF patients and for working capital.
- Loan amendment with SVB: upon raising $45M net equity, milestones terminate; interest rate becomes prime+3% (floor 6.25%).

## SEC filing metadata
- accession: 0001193125-22-098229
- form_type: 8-K
- ticker: TRVI
- cik: 0001563880
- company_name: Trevi Therapeutics, Inc.
- filed_at: 2022-04-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563880/000119312522098229/0001193125-22-098229-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563880/000119312522098229/d324144d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-098229
- JSON: https://secwatch.observer/filing/0001193125-22-098229.json
- Plain text: https://secwatch.observer/filing/0001193125-22-098229.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.